NCT06995508 2026-02-17
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05705492 2026-01-21
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT03118986 2025-10-08
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
Phase 2 Recruiting
NCT05170919 2024-09-19
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
Englewood Hospital and Medical Center
Phase 2 Enrolling by invitation
NCT06554613 2024-08-15
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT04669132 2022-02-23
OLNEPA
Instituto Brasileiro de Controle do Cancer
Phase 2 Completed
NCT05202275 2022-01-21
The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs
ChineseAMS
Phase 2 Unknown
NCT03960151 2019-05-22
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03679182 2018-09-20
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
Khon Kaen University
Phase 2 Unknown
NCT03575637 2018-07-03
Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
Peking University
Phase 2 Unknown
NCT02400866 2015-03-27
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
Korean South West Oncology Group
Phase 2 Unknown
NCT02290470 2014-11-14
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown